title: Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for central serous chorioretinopathy.
abstract: To evaluate subfoveal choroidal thickness (SFCT) changes after intravitreal bevacizumab (IVB) therapy for central serous chorioretinopathy (CSC) using enhanced depth imaging spectral-domain optical coherence tomography (EDI-OCT).
  In this retrospective study, we assessed the medical records of patients with CSC who received IVB (IVB group) or who were observed without intervention (control group). SFCT was measured using EDI-OCT. The main outcome measure was the change in SFCT.
  Twenty-one eyes were included in the IVB group and 16 eyes were included in the control group. All patients showed resolution of neurosensory detachment and improvement in vision. In the IVB group, the mean SFCT was 315 μm at baseline, which decreased to 296 μm at the most recent visit. In the control group, the mean SFCT was 307 μm at baseline, which decreased to 266 μm at the most recent visit. Although there was a significant decrease in the mean SFCT for the control group, the decrease was not significant for the IVB group (41 vs 19 μm, p=0.003 vs p=0.071).
  SFCT decreased in both groups with remission of the disease. However, the decrease was significantly greater in the control group. In terms of anatomic and functional outcomes, IVB injection is not promising.
authors.affiliation: Opthalmology Department, Ümraniye Training and Research Hospital, İstanbul, Turkey.
authors.forename: Cihan
authors.initials: C
authors.lastname: Ünlü
authors.affiliation: Opthalmology Department, Ümraniye Training and Research Hospital, İstanbul, Turkey.
authors.forename: Gurkan
authors.initials: G
authors.lastname: Erdogan
authors.affiliation: Opthalmology Department, Ümraniye Training and Research Hospital, İstanbul, Turkey.
authors.forename: Tugba Aydogan
authors.initials: TA
authors.lastname: Gezginaslan
authors.affiliation: Opthalmology Department, Ümraniye Training and Research Hospital, İstanbul, Turkey.
authors.forename: Betul Ilkay Sezgin
authors.initials: BI
authors.lastname: Akcay
authors.affiliation: Opthalmology Department, Ümraniye Training and Research Hospital, İstanbul, Turkey.
authors.forename: Esra
authors.initials: E
authors.lastname: Kardes
authors.affiliation: Opthalmology Department, Ümraniye Training and Research Hospital, İstanbul, Turkey.
authors.forename: Tahir Kansu
authors.initials: TK
authors.lastname: Bozkurt
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D056833:Central Serous Chorioretinopathy / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D002829:Choroid / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab